63 results
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
or political subdivision, department or agency of a government;
“Phase II” means a human clinical trial of a Product in any country that would satisfy … , exemption of, or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic
10-K
2023 FY
EX-19.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
an insider trading investigation conducted either by the U.S. Securities and Exchange Commission (the “SEC”) or the U.S. Department of Justice, even
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
agreement. See "—Material Agreements—Licensing Agreement for Leflutrozole".
Government Regulation
Among others, the FDA, U.S. Department of Health … permits the Secretary of the Department of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
7 Sep 23
Current report (foreign)
7:37am
to the Nasdaq Capital Market. On May 8, 2023, the Company received notification from the Nasdaq Listings Qualifications Department that the ADSs had
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
8 May 23
Current report (foreign)
4:07pm
the Nasdaq Listings Qualifications Department that the ADSs had, for the last 10 consecutive business days, a closing bid price at $1.00 per share
6-K
4l5fp
8 May 23
Current report (foreign)
4:07pm
6-K
1dlgbeq57s wnabz5g
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
EX-99.1
g5xnfs0 aml
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
EX-99.2
z0524c7
2 Nov 22
Current report (foreign)
4:17pm
6-K
ccqljh
2 Nov 22
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
4:07pm
6-K
EX-99.1
dfioty1e n0
2 Nov 22
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
4:07pm
6-K
EX-99.2
24sdbsmr4
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
wswcxb jwzgon1br823
5 Jul 22
Current report (foreign)
4:15pm
6-K
tyaf7s3nick
25 May 22
Current report (foreign)
4:11pm
F-6EF
EX-99
imu0swr7jy610oz
13 Aug 21
Automatic registration for ADRs (foreign)
5:24pm